BLOOD

Scope & Guideline

Illuminating Innovations in Hematology and Immunology.

Introduction

Immerse yourself in the scholarly insights of BLOOD with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0006-4971
PublisherAMER SOC HEMATOLOGY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1946 to 2024
AbbreviationBLOOD / Blood
Frequency52 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2021 L ST NW, SUITE 900, WASHINGTON, DC 20036

Aims and Scopes

The journal 'BLOOD' focuses on advancing the field of hematology through innovative research that encompasses various aspects of blood disorders, including their biology, diagnosis, treatment, and patient management.
  1. Hematologic Malignancies:
    A core focus of the journal is on hematologic cancers such as leukemia, lymphoma, and myeloma, including studies on their molecular mechanisms, therapeutic strategies, and clinical outcomes.
  2. Transfusion Medicine and Hemostasis:
    Research related to blood transfusion practices, coagulation disorders, and the management of bleeding disorders is prominently featured, emphasizing both clinical and laboratory aspects.
  3. Genomics and Precision Medicine:
    The journal publishes studies on the genetic basis of blood disorders and the application of genomic technologies to personalize treatment approaches.
  4. Immunotherapy and Novel Therapeutics:
    There is a significant focus on immunotherapeutic strategies, including CAR T-cell therapies and monoclonal antibodies, aimed at treating various hematologic malignancies.
  5. Patient-Centered Care and Quality of Life:
    Research addressing the psychosocial aspects of hematologic diseases, including patient-reported outcomes and the impact of treatment on quality of life, is increasingly emphasized.
  6. Clinical Trials and Real-World Evidence:
    The journal highlights findings from clinical trials as well as real-world studies that provide insights into treatment effectiveness and safety in diverse populations.
The journal 'BLOOD' has witnessed a notable evolution in its scope, with emerging themes reflecting the latest advancements in hematologic research and clinical practice. These trends highlight the journal's commitment to addressing contemporary challenges in hematology.
  1. CAR T-Cell Therapy:
    There is a significant increase in research related to CAR T-cell therapies, including their development, efficacy, and management of associated toxicities, reflecting the growing importance of this treatment modality in hematologic malignancies.
  2. Genetic and Molecular Profiling:
    Studies focusing on genetic mutations, epigenetic changes, and their implications for disease progression and treatment response are becoming increasingly prevalent, emphasizing the role of precision medicine in hematology.
  3. Real-World Evidence and Health Economics:
    The journal is increasingly publishing articles that analyze real-world data to evaluate treatment outcomes and healthcare costs, highlighting the importance of pragmatic approaches in clinical decision-making.
  4. Immunotherapy Combinations:
    Emerging research on combining immunotherapies with other treatment modalities, such as targeted therapies and traditional chemotherapy, is gaining momentum, indicating a shift towards multi-faceted treatment strategies.
  5. Patient-Centered Research:
    An emphasis on patient-reported outcomes, quality of life assessments, and studies addressing the psychosocial aspects of hematologic diseases is becoming more pronounced, reflecting a holistic approach to patient care.

Declining or Waning

While the journal 'BLOOD' continues to explore a wide array of topics within hematology, certain areas have seen a decrease in focus or publication frequency over the years, reflecting evolving research priorities and advancements in the field.
  1. Traditional Chemotherapy Approaches:
    There is a declining emphasis on classical chemotherapy regimens for hematologic malignancies as newer targeted therapies and immunotherapies gain prominence.
  2. Basic Hematology Research:
    Research focused solely on basic hematology without immediate clinical application appears to be waning, as the journal increasingly prioritizes translational and clinical studies.
  3. Epidemiological Studies:
    While still relevant, the volume of purely epidemiological studies on blood disorders has decreased, with a shift towards more integrated approaches that combine clinical outcomes with genomic and molecular data.
  4. Single-Agent Therapy Studies:
    The focus on studies evaluating the efficacy of single-agent therapies has diminished, as combination therapies are recognized for their enhanced effectiveness in treating complex hematologic conditions.
  5. Niche Hematologic Disorders:
    Research on less common hematologic conditions may be receiving less attention in favor of more prevalent disorders and broader therapeutic strategies.

Similar Journals

HemaSphere

Transforming knowledge into patient care advancements.
Publisher: WILEYISSN: Frequency: 12 issues/year

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

Indian Journal of Hematology and Blood Transfusion

Advancing Hematology: Unveiling Insights for Better Blood Health
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

Hemato

Connecting Scholars for Impactful Hematological Research
Publisher: MDPIISSN: Frequency: 4 issues/year

Hemato is a pioneering open-access journal dedicated to the field of hematology, published by the esteemed MDPI from its base in Basel, Switzerland. Launched in 2020, this journal aims to provide a platform for researchers, clinicians, and professionals to share significant findings and advancements in blood-related disciplines over a converged timeframe until 2024. With a commitment to disseminating high-quality research, Hemato seeks to foster collaboration and innovation in hematological studies, showcasing original articles, reviews, and clinical studies that contribute to expanding knowledge in this vital area. As an open-access journal, it promotes accessible scholarship, ensuring that groundbreaking research reaches a broad audience, thereby enhancing the impact on the global health community.

TRANSFUSION MEDICINE AND HEMOTHERAPY

Transforming patient care through cutting-edge research.
Publisher: KARGERISSN: 1660-3796Frequency: 6 issues/year

TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.

BLOOD REVIEWS

Empowering research, transforming blood health.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

CURRENT OPINION IN HEMATOLOGY

Empowering clinicians and researchers with cutting-edge insights.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Blood Research

Connecting Researchers to Revolutionize Blood Health
Publisher: SPRINGERISSN: 2287-979XFrequency: 4 issues/year

Blood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.

Blood Transfusion

Enhancing Lives Through Blood Transfusion Innovations.
Publisher: SIMTIPRO SRLISSN: 1723-2007Frequency: 6 issues/year

Blood Transfusion is a leading journal in the fields of Hematology, Immunology, and Medicine, published by SIMTIPRO SRL in Italy. With its ISSN 1723-2007, the journal has established a significant presence in the academic community, as evidenced by its positioning within the Q2 category in Hematology and Medicine (miscellaneous) and Q3 in Immunology and Allergy for 2023. Notably, it ranks #38 out of 137 in the Hematology category, showcasing its impactful contributions to research and practice. Operating under a traditional publishing model, this journal provides valuable insights into advances in blood transfusion science, ultimately aimed at enhancing patient care and outcomes. Spanning from 2003 to 2024, the scope of Blood Transfusion covers a wide range of topics related to hematological and immunological research, making it an essential resource for researchers, healthcare professionals, and students engaged in these critical fields.

AMERICAN JOURNAL OF HEMATOLOGY

Connecting Scholars to Shape the Future of Hematology
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

EUROPEAN JOURNAL OF HAEMATOLOGY

Transforming Hematology Through Rigorous Research
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.